Ovarian cancer is a lethal gynaecological malignancy that affects over 295,000 women globally, with a 20% survival rate for advanced stage. Often diagnosed at a late stage, due to the non-specific nature of symptoms, detection of ovarian cancer at an early stage is paramount. The discovery of novel hormones and influencers of the tumour microenvironment provide a promising avenue of research for the identification of cancer biomarkers. This project aims to expand research of a novel glucogenic hormone within the tumour microenvironment using traditional mono-layer tissue culture techniques as well as 3D co-culture organ-on-a-chip technology in addition to clinical liquid biopsies in order to advance the molecular understanding of ovarian cancer aetiology.
Meet the Principal Investigator(s) for the project
Dr Emmanouil Karteris - Dr Manos Karteris graduated with a BSc (Hons) in Medical Biochemistry from the University of Surrey in 1995. He then was awarded an MSc with Distinction in Medical Genetics with Immunology from СʪÃÃÊÓƵ London in 1996 and completed his PhD in Molecular Endocrinology from the University of Warwick in 2000. He then undertook post-doctoral appointments at the University of Warwick, including a prestigious VIP Research Fellowship from the Wellcome Trust. He was appointed as Lecturer in Endocrinology at the University of Warwick from 2005-2006 and then he transferred to СʪÃÃÊÓƵ London as a Lecturer in Biomedical Sciences in June 2006. Currently he is a Reader in the Division of Biomedical Sciences. Dr Karteris is the Departmental Director International.
Related Research Group(s)
Organ-on-a-Chip - The group’s main research focus is on women’s health and developing four main organ-on-a-chip (OOC) models: the breast, vagina, ovary, and placenta.
Partnering with confidence
Organisations interested in our research can partner with us with confidence backed by an external and independent benchmark: The Knowledge Exchange Framework. Read more.
Project last modified 21/11/2023